Literature DB >> 11504071

Diagnosis of late-infantile neuronal ceroid lipofuscinosis: a new sensitive method to assay lysosomal pepstatin-insensitive proteinase activity in human and animal specimens by capillary electrophoresis.

S Viglio1, E Marchi, K Wisniewski, B Casado, G Cetta, P Iadarola.   

Abstract

Batten disease, or human late-infantile neuronal ceroid lipofuscinosis (LINCL) is a familiar progressive degenerative disease affecting children, caused by a deficiency of a lysosomal proteinase (tripeptidyl peptidase I, TPP-I) and characterized by the accumulation of autofluorescent storage bodies in the brain and other tissues of the body. Current methodology used to diagnose this disease needs to be improved in order to have less invasive techniques with higher resolution and shorter assay time. In this report, we discuss the potential merits of micellar electrokinetic chromatography as an excellent tool that requires minute samples but offers high resolution and a short running time for monitoring TPP-I activity in human and animal specimens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504071     DOI: 10.1002/1522-2683(20017)22:11<2343::AID-ELPS2343>3.0.CO;2-2

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  2 in total

1.  Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease therapy.

Authors:  Sudipta Chakrabarti; Sujyoti Chandra; Avik Roy; Sridevi Dasarathi; Madhuchhanda Kundu; Kalipada Pahan
Journal:  Neurobiol Dis       Date:  2019-03-28       Impact factor: 5.996

2.  Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: implications for late infantile Batten disease therapy.

Authors:  Arunava Ghosh; Grant T Corbett; Frank J Gonzalez; Kalipada Pahan
Journal:  J Biol Chem       Date:  2012-09-18       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.